Audentes Therapeutics, Inc. (NASDAQ:BOLD) is among the top stocks that may remain in focus today as the company shares are trading 3.89% or 1.21 points higher from last closing price of $31.08, reaching $32.29 at last check. Any clue why there is so much of action in the BOLD stock? The share price has risen in 4 of the last 5 days and is down -15.29% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -77,628 shares, and in total 232772 shares valued at $7.516 million were seen changing hands compared with 310400 shares valued at $9.647 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in BOLD stock for the next couple of days.
Audentes Therapeutics, Inc. (BOLD) shares have notched a 3-month decline of about -15.29%, but has still advanced 45.78% year to date. By comparison, the stock sank -11.21% over the past 12 months, while it slipped -12.38% over the 1 month. The company’s market cap is around $1.44B, with its short interest ratio standing at 4.6%.
In the current trading session for BOLD, the stock witnessed two major price actions, it rose to a high of $32.39 and was down as much as $30.95 at one point. The high recorded is very low when compared to their 52-week high which is $17.95. The 52-week high is now at -22.55 distance from current price. Their recent low of $41.65 represents a 79.72% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for BOLD is $45.75, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The company recorded an interesting insider sale transaction by the CEO on Aug 12, 2019. A Securities and Exchanges Commission filings show that Matthew R Patterson sold a total of 20,000 BOLD shares that day for a sum of around $680,800. The filings show that the insider now retains 135,368 shares, currently worth $4,371,033. Audentes Therapeutics, Inc. (BOLD) insiders have acquired 30,000 shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to 43,984 shares. In total, individual insiders traded 73,984 shares in the business, which makes up 16.728% of 442,283 shares that were traded over a year. In the past 12 months, insiders have purchased 196,595 shares while the seller parted with 245,688 shares.
BOLD‘s last price was down -0.87% as compared to the average trading price of 50 days recorded at $32.57 while enlarging the period to 200 trading days, the average closing price was $35.11. At present, there are 46.28 million in the total number of common shares owned by the public and among those 41.95 million shares have been available to trade. The percentage of shares being held by the company management was 1.2% while institutions stake was 0%. The company has generated negative returns on equity over the last 12 months (-42.2%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the BOLD stock, there is another set of technicals that should be looked into and considered. Its 1.1% gain from moving average of $31.94 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Audentes Therapeutics, Inc. — 11 analysts rate the stock as a buy with another 0 rating it strong buy. There are 2 analysts who maintain a hold rating for the stock, with 2 giving it a sell rating. Analysts arrived at a 12-month price target of $42.4925 on shares of Audentes Therapeutics, Inc. (NASDAQ:BOLD), which corresponds to 31.96% upside potential than its current market price of $32.29 and implies potential despite the recent advance in the price. However, their current target price has climbed from $39.9931 a month ago and is up handily from the consensus target of $39.9931 a quarter ago.
In the last five years, the EPS of the company has been roughly 0%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 13.2%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards BOLD stock. Orbimed Advisors LLC trimmed position in the company after it dumped -5.6% or 1,814,692 shares of its common stock. The hedge fund now owns 1,713,069 shares worth $55,314,998, SEC documents show. Cowen Inc. cut assets in the stock as 77938.78 shares have been sold, reducing its stake by -51% to 38,190 shares which are currently valued at $1,233,155. In addition, United Services Automobile Association recently reported that it now owns 47,531 shares making a total of $1,534,776 based on the recent price. This refelects a change of -13.2% in their ownership.